SCHEMBL6133312

SCHEMBL6133312

C=CC(=O)OCC(CC)CCCC.C=CC(=O)OCCCC.C=CCOC(=O)C=C.C=COC(C)=O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 7/20 0.64
HPGD P15428 1/20 0.49
CYP3A4 P08684 5/20 0.41
TDP1 Q9NUW8 2/20 0.41
ATM Q13315 2/20 0.41
RECQL P46063 1/20 0.39
ALDH1A1 P00352 5/20 0.38
CA2 P00918 1/20 0.38
HCAR2 Q8TDS4 1/20 0.35
LMNA P02545 2/20 0.35
MAPT P10636 1/20 0.34
RAB9A P51151 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
MAPK1 P28482 1/20 0.34
HSD17B10 Q99714 1/20 0.34
PRSS1 P07477 1/20 0.34
PRSS2 P07478 1/20 0.34
PRSS3 P35030 1/20 0.34
MMP9 P14780 1/20 0.33
MMP8 P22894 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6134355 0.96 TSHR (0.59) TSHRHPGDCYP3A4TDP1ATM
SCHEMBL6133318 0.95 TSHR (0.71) TSHRHPGDCYP3A4TDP1ATM
SCHEMBL6133965 0.94 TSHR (0.72) TSHRHPGDCYP3A4TDP1ATM
Acrylic Acid SCHEMBL16151343 0.91 TSHR (0.67) TSHRHPGDCYP3A4TDP1ATM
SCHEMBL6416885 0.90 TSHR (0.66) TSHRHPGDCYP3A4TDP1ATM
SCHEMBL560438 0.89 TSHR (0.81) TSHRHPGDCYP3A4TDP1ATM
SCHEMBL7263170 0.88 TSHR (0.63) TSHRHPGDCYP3A4TDP1ATM
SCHEMBL6746745 0.88 TSHR (0.66) TSHRHPGDCYP3A4TDP1ATM
SCHEMBL561230 0.87 TSHR (0.69) TSHRHPGDCYP3A4TDP1ATM
Ethylene SCHEMBL9340940 0.87 TSHR (0.64) TSHRHPGDCYP3A4TDP1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050226919-A1 Device for transdermal administration for the treatment of urinary tract disorders UCB PHARMA GMBH (DE) 2005-10-13 US disclosed
EP-1293198-B1 Device for transdermal administration for the treatment of urinary tract disorders SANOL ARZNEI SCHWARZ GMBH (DE) 2005-02-09 EP disclosed
WO-2003024432-A2 DEVICE FOR TRANSDERMAL ADMINISTRATION FOR THE TREATMENT OF URINARY TRACT DISORDERS SCHWARZ PHARMA AG (DE) 2003-03-27 WO disclosed
EP-1293198-A1 Device for transdermal administration for the treatment of urinary tract disorders SCHWARZ PHARMA AG (DE) 2003-03-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050226919-A1 Device for transdermal administration for the treatment of urinary tract disorders AR, CYP17A1, TACR1 TSHR 465/4885HPGD 287/4885CYP3A4 880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.